Through the Innowwide-supported CareSync project, we will strengthen the external validation of our technology in a new care setting.
Aisthesis Medical is proud to announce that we’ve been awarded a EUREKA Innowwide Grant for our international collaboration project, Next-Generation AI Screening Tool for Sepsis Detection and Prevention. This competitive grant supports cross-border innovation partnerships and marks a significant milestone as we expand the clinical validation and global reach of our flagship AI platform, VIOSync®.
Pioneering Predictive Sepsis Care — Across Borders
This project represents a transatlantic collaboration between Aisthesis Medical (UK & Greece), Caretaker Medical (USA) , and Carilion Clinic (USA). Through this partnership, we will:
- Validate VIOSync® using real-world data collected from Caretaker Medical’s continuous, non-invasive wearable devices.
- Conduct a summative usability study at Carilion Clinic, a leading academic health system in Virginia, to evaluate clinician interaction and workflow integration.
- Build pathways for regulatory alignment and product deployment in the US market, starting with clinical evidence generation and hospital implementation readiness.
Why It Matters
Every year, sepsis affects nearly 50 million people globally and remains a leading cause of death in hospitals. VIOSync® is designed to change that. By predicting sepsis up to 48 hours in advance using multimodal data and Explainable AI (XAI), VIOSync® enables clinicians to act earlier, reduce ICU admissions, and save lives.
Through the Innowwide-supported CareSync project, we will strengthen the external validation of our technology in a new care setting, ensuring VIOSync® is safe, effective, and interoperable with cutting-edge monitoring solutions.
About the Innowwide Programme
The EUREKA Innowwide programme funds innovative European SMEs aiming to explore international markets through collaborative R&D. With a focus on commercialization
and global impact, the programme helps promising tech companies like Aisthesis Medical develop partnerships and validate solutions beyond their borders.
Learn more: EUREKA Innowwide
Looking Ahead
This project lays the groundwork for regulatory submissions and early commercial deployment of VIOSync® in the United States. It also opens the door to long-term collaboration with US-based medtech companies and healthcare providers eager to adopt evidence-based AI for critical care.
As we continue to scale, we invite hospitals, research institutions, and digital health partners to join us in advancing precision care for sepsis and other acute conditions.
About Aisthesis Medical
Aisthesis Medical is a UK-based clinical AI company transforming how hospitals predict and respond to critical illness. Founded in 2022, we develop regulation-ready, explainable AI platforms to enable earlier, safer, and more personalised interventions in acute care.
Our flagship platform, VIOSync®, is an end-to-end sepsis care solution that predicts deterioration up to 48 hours in advance, guides treatment through protocol-based decision support, and integrates directly into EHR workflows. Unlike retrospective or opaque black-box models, VIOSync® is designed for the frontline — combining digital patient twins, explainable risk scores, and clinical pathway automation.